ADHESION
Development of new biotech AdvanceD materials based on Hyaluronic acid and nanoparticlEs to prevent Surgical adhesIons and pOst surgical infectionNs
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0ADHESION project word cloud
Explore the words cloud of the ADHESION project. It provides you a very rough idea of what is the project "ADHESION" about.
Project "ADHESION" data sheet
The following table provides information about the project.
| Coordinator |
NOVAGENIT SRL
Organization address contact info |
| Coordinator Country | Italy [IT] |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology) 2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument) |
| Code Call | H2020-SMEINST-1-2014 |
| Funding Scheme | SME-1 |
| Starting year | 2015 |
| Duration (year-month-day) | from 2015-05-01 to 2015-10-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | NOVAGENIT SRL | IT (MEZZOLOMBARDO) | coordinator | 50˙000.00 |
Map
Project objective
The aim of the ADHESION Project is to strengthen the anti-adhesion and anti-bacterial characteristics of a NOVAGENIT® proprietary product (DAC®), by tuning and validating a new more competitive solution targeted to the orthopaedic and cardiovascular surgery. NOVAGENIT® will take the opportunity to expand its own business in the anti-adhesion market by taking advantage of the intrinsic barrier effect of the DAC® hydrogel. A new formulation of the DAC® product will add an anti-bacterial power to the anti-fouling/anti-adhesion intrinsic action. This could be due to a combination of silver nano-particles and to Vitamin C added to the derivatized hyaluronan based gel original formulation. The new formulation, comprising a lyophilized membrane, will increase the usability for the end user, and will prolong the shelf life of the biotech, advanced material product.NOVAGENIT® intends to address both the adhesion and infection issues, as it is a complete novelty in the market of anti-adhesion products. Specifically the business opportunity consists in the combination of the three key product features (anti-fouling, antibiotic and usability) into a novel product not yet market available, and to target two surgery markets (cardiovascular and orthopaedic ones) in order to generate the appropriate return on the investment. This phase 1 consists in the feasibility study devoted to assess the economic/technological viability of the innovative idea and to generate its business plan. It will be followed by a phase 2 where the product will be industrialized and make ready for sales through a targeted marketing plan. The envisaged advantage for the European Health-care system from the results of the ADHESION Project is to spare the costs of re-interventions, both for the post-surgical adhesions (about 2 billion Euros/year), and the post-surgical infections (about 3 to 5 billion Euros/year). Future opportunities of this product on different markets will be exploited.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ADHESION" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "ADHESION" are provided by the European Opendata Portal: CORDIS opendata.